FDA Clearance Tracker · P250004
MMR IHC Panel pharmDx (Dako Omnis)
Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Aug 15, 2025
Approved
Time to decision
178 days
Received Feb 18, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P250004
- Device name
- MMR IHC Panel pharmDx (Dako Omnis)
- Applicant
- Agilent Technologies, Inc.
- Applicant location
- Carpinteria, CA
- Received
- Feb 18, 2025
- Decided
- Aug 15, 2025
- Decision
- Approved
- Supplements
- 1 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Regulation
- 21 CFR 864.1860
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
For In Vitro Diagnostic Use.MMR IHC Panel pharmDx (Dako Omnis) is a qualitative immunohistochemical (IHC) assay intended for use in the assessment of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6) in formalin-fixed, paraffin-embedded (FFPE) colorectal cancer (CRC) tissue using EnVision FLEX visualization system on Dako Omnis automated staining instrument. MMR IHC Panel pharmDx (Dako Omnis) consists of MLH1 IHC pharmDx (Dako Omnis), PMS2 IHC pharmDx (Dako Omnis), MSH2 IHC pharmDx (Dako Omnis), and MSH6 IHC pharmDx (Dako Omnis), which must be used together to identify MMR deficient CRC patients.MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify MMR deficient CRC patients eligible for treatment with OPDIVO® (nivolumab) alone or OPDIVO (nivolumab) in combination with YERVOY® (ipilimumab).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QNH. The earliest in FDA's data is P200019, decided Apr 22, 2021.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Agilent Technologies, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PD-L1 IHC 28-8 pharmDxPMA supplement
P150025-S018 · Decided Jul 1, 2026 · 180 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- PD-L1 IHC 22C3 pharmDxPMA supplement
P150013-S032 · Decided Feb 11, 2026 · 187 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- PD-L1 IHC 22C3 pharmDxPMA supplement
P150013-S033 · Decided Feb 10, 2026 · 134 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.